Sec Form 3 Filing - ZELDIS JEROME B @ BioSig Technologies, Inc. - 2019-05-17

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person ZELDIS JEROME B 2. Issuer Name and Ticker or Trading Symbol BioSig Technologies, Inc. [ BSGM] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O BIOSIG TECHNOLOGIES, INC., 12424 WILSHIRE BLVD, SUITE 745 3. Date of Earliest Transaction (MM/DD/YY) 05/17/2019 (Street) LOS ANGELES, CA90025 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock, $0.001 par value per share 68,709 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Options to Purchase Common Stock $ 9.975 04/09/2015 04/09/2025 Common Stock 120,000 D Options to Purchase Common Stock $ 6.325 ( 1 ) 06/22/2025 Common Stock 20,000 D Options to Purchase Common Stock $ 3.4 12/22/2016 12/22/2026 Common Stock 20,000 D Series C Preferred Stock $ 3.75 ( 2 ) ( 2 ) ( 2 ) Common Stock 13,334 ( 3 ) D Warrants to Purchase Common Stock $ 6.85 ( 4 ) 08/17/2021 Common Stock 1,097 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other ZELDIS JEROME B C/O BIOSIG TECHNOLOGIES, INC. 12424 WILSHIRE BLVD, SUITE 745 LOS ANGELES, CA90025 X Signatures /s/ Kenneth L. Londoner, attorney-in-fact 05/22/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The options vested in 12 consecutive monthly installments beginning one month from June 22, 2015, the date of the grant. As of the date of this report, the options are fully vested and exercisable. ( 2 )The Series C Preferred Stock may be converted at any time at the option of the holder into shares of common stock at a conversion price of $3.75 per share. The Series C Preferred Stock has no expiration date. ( 3 )Each share of the Series C Preferred Stock is entitled to a nine percent (9%) annual dividend on the $1,000 per share stated value. Unless the Series C Preferred Stock is converted into shares of common stock, the dividends shall accrue and be payable in cash or, at the Issuer's option and subject to the satisfaction of certain conditions, in pay-in-kind shares. Such cumulative dividends are payable quarterly, commencing on September 30, 2013, thereafter quarterly on December 31, March 31, June 30 and September 30, and on each conversion date. ( 4 )The warrants were issued on August 17, 2018, and are exercisable as of the date of this report.

Remarks: Exhibit IndexExhibit 24.1 Power of Attorney (furnished herewith)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.